Protein Induced by Vitamin K Absence or Antagonist-II Versus Alpha-Fetoprotein in the Diagnosis of Hepatocellular Carcinoma: A Systematic Review With Meta-Analysis.
Alpha-fetoprotein
Hepatitis B virus
Hepatitis C virus
Hepatocellular carcinoma
Vitamin K absence or antagonist-II
Journal
Journal of clinical medicine research
ISSN: 1918-3003
Titre abrégé: J Clin Med Res
Pays: Canada
ID NLM: 101538301
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
13
05
2023
accepted:
09
06
2023
medline:
14
8
2023
pubmed:
14
8
2023
entrez:
14
8
2023
Statut:
ppublish
Résumé
Protein induced by vitamin K absence or antagonist-II (PIVKA-II) and α-fetoprotein (AFP) are promising tumor markers for the diagnosis of hepatocellular carcinoma (HCC). Yet, their diagnostic performance differs throughout HCC investigations. The aim of this meta-analysis was to assess the effectiveness of PIVKA-II and AFP in the diagnosis of HCC. A systematic literature search was performed to identify relevant studies from eight databases, which were published up to February 2023, in order to compare the diagnostic performance of PIVKA-II and AFP for HCC. Pooled sensitivity and specificity were calculated. Summary receiver operating characteristic (SROC) curve was performed to assess the diagnostic accuracy of each biomarker. Fifty-three studies were identified. The pooled sensitivity (95% confidence interval (CI)) of PIVKA-II and AFP was 0.71 (0.70 - 0.72) and 0.64 (0.63 - 0.65), respectively in diagnosis of HCC, and the corresponding pooled specificity (95% CI) was 0.90 (0.89 - 0.90) and 0.87 (0.87 - 0.88), respectively. The area under the ROC curve (AUC) of PIVKA-II and AFP was 0.89 (0.88 - 0.90) and 0.78 (0.77 - 0.79), respectively. Subgroup analysis demonstrated that PIVKA-II presented higher AUC values compared to AFP in terms of ethnic group (African, European, Asian, and American patients), etiology (mixed-type HCC, hepatitis C virus (HCV)-related, and hepatitis B virus (HBV)-related) and sample size of cases (≤ 100 and > 100). This study reveals that PIVKA-II is a promising biomarker for identifying and tracking HCC, exhibiting greater accuracy than AFP. Our findings indicate that PIVKA-II outperforms AFP in detecting HCC across diverse racial groups and sample sizes, as well as in cases of HBV-related, HCV-related, or mixed-etiology HCC.
Sections du résumé
Background
UNASSIGNED
Protein induced by vitamin K absence or antagonist-II (PIVKA-II) and α-fetoprotein (AFP) are promising tumor markers for the diagnosis of hepatocellular carcinoma (HCC). Yet, their diagnostic performance differs throughout HCC investigations. The aim of this meta-analysis was to assess the effectiveness of PIVKA-II and AFP in the diagnosis of HCC.
Methods
UNASSIGNED
A systematic literature search was performed to identify relevant studies from eight databases, which were published up to February 2023, in order to compare the diagnostic performance of PIVKA-II and AFP for HCC. Pooled sensitivity and specificity were calculated. Summary receiver operating characteristic (SROC) curve was performed to assess the diagnostic accuracy of each biomarker.
Results
UNASSIGNED
Fifty-three studies were identified. The pooled sensitivity (95% confidence interval (CI)) of PIVKA-II and AFP was 0.71 (0.70 - 0.72) and 0.64 (0.63 - 0.65), respectively in diagnosis of HCC, and the corresponding pooled specificity (95% CI) was 0.90 (0.89 - 0.90) and 0.87 (0.87 - 0.88), respectively. The area under the ROC curve (AUC) of PIVKA-II and AFP was 0.89 (0.88 - 0.90) and 0.78 (0.77 - 0.79), respectively. Subgroup analysis demonstrated that PIVKA-II presented higher AUC values compared to AFP in terms of ethnic group (African, European, Asian, and American patients), etiology (mixed-type HCC, hepatitis C virus (HCV)-related, and hepatitis B virus (HBV)-related) and sample size of cases (≤ 100 and > 100).
Conclusion
UNASSIGNED
This study reveals that PIVKA-II is a promising biomarker for identifying and tracking HCC, exhibiting greater accuracy than AFP. Our findings indicate that PIVKA-II outperforms AFP in detecting HCC across diverse racial groups and sample sizes, as well as in cases of HBV-related, HCV-related, or mixed-etiology HCC.
Identifiants
pubmed: 37575350
doi: 10.14740/jocmr4951
pmc: PMC10416192
doi:
Banques de données
Dryad
['10.5061/dryad.3n901']
Types de publication
Journal Article
Langues
eng
Pagination
343-359Informations de copyright
Copyright 2023, Kobeissy et al.
Déclaration de conflit d'intérêts
All other authors have no conflict of interest to disclose.
Références
Scand J Gastroenterol. 2016 Mar;51(3):344-53
pubmed: 26340708
Lab Med. 2021 Jul 1;52(4):381-389
pubmed: 33159511
Tumour Biol. 2017 Jun;39(6):1010428317705763
pubmed: 28621228
J Clin Lab Anal. 2023 Jan;37(1):e24823
pubmed: 36579611
Scand J Gastroenterol. 2019 Oct;54(10):1283-1290
pubmed: 31593481
Biosci Trends. 2014 Oct;8(5):266-73
pubmed: 25382443
Cancer. 1994 May 15;73(10):2464-71
pubmed: 7513601
J Interv Med. 2021 Mar 16;4(2):77-81
pubmed: 34805952
PLoS One. 2016 Apr 12;11(4):e0153227
pubmed: 27070780
J Int Med Res. 2020 Oct;48(10):300060520969087
pubmed: 33135527
Sci Rep. 2020 Aug 11;10(1):13519
pubmed: 32782270
Int J Gen Med. 2022 Jun 23;15:5763-5773
pubmed: 35770053
BMJ. 2009 Jul 21;339:b2700
pubmed: 19622552
Hepatology. 2003 May;37(5):1114-21
pubmed: 12717392
Cancers (Basel). 2020 Oct 31;12(11):
pubmed: 33142893
Scand J Clin Lab Invest. 2017 May;77(3):175-183
pubmed: 28276727
Dis Markers. 2021 Feb 08;2021:8868370
pubmed: 33628341
Lab Med. 2022 Sep 1;53(5):488-494
pubmed: 35551399
Medicina (Kaunas). 2022 Jul 28;58(8):
pubmed: 36013482
J Clin Med. 2022 Aug 29;11(17):
pubmed: 36079006
Cancer Med. 2022 May;11(9):1995-2005
pubmed: 35261196
JGH Open. 2022 May 07;6(5):292-300
pubmed: 35601131
Clin Gastroenterol Hepatol. 2009 Jan;7(1):104-13
pubmed: 18849011
JAMA Netw Open. 2020 Jan 3;3(1):e1919325
pubmed: 31922554
Hepatol Int. 2008 Mar;2(1):17-30
pubmed: 19669276
Scand J Gastroenterol. 2016 Oct;51(10):1257-62
pubmed: 27227515
Ann Intern Med. 2011 Oct 18;155(8):529-36
pubmed: 22007046
Hepatobiliary Pancreat Dis Int. 2022 Dec;21(6):559-568
pubmed: 35643910
J Gastroenterol Hepatol. 1989 Jan-Feb;4(1):17-24
pubmed: 2485005
Eur J Clin Invest. 2008 Aug;38(8):571-7
pubmed: 18625005
World J Gastroenterol. 2015 Apr 7;21(13):3928-35
pubmed: 25852278
BMC Cancer. 2021 Apr 13;21(1):401
pubmed: 33849479
Gastroenterology. 2009 Jul;137(1):110-8
pubmed: 19362088
J Gastroenterol Hepatol. 1992 Jan-Feb;7(1):1-6
pubmed: 1371940
Int J Mol Med. 2002 Mar;9(3):245-50
pubmed: 11836630
World J Gastroenterol. 2005 Oct 21;11(39):6115-9
pubmed: 16273636
Medicine (Baltimore). 2017 Mar;96(11):e5811
pubmed: 28296720
Cold Spring Harb Perspect Med. 2020 Apr 1;10(4):
pubmed: 31636094
Br J Cancer. 2003 Jun 16;88(12):1878-82
pubmed: 12799630
Hepatol Int. 2017 Jul;11(4):317-370
pubmed: 28620797
J Clin Lab Anal. 2020 May;34(5):e23158
pubmed: 31821607
Int J Cancer. 2010 Dec 15;127(12):2893-917
pubmed: 21351269
PLoS One. 2016 Mar 17;11(3):e0151069
pubmed: 26986465
Res Synth Methods. 2010 Apr;1(2):97-111
pubmed: 26061376
World J Gastroenterol. 2013 Jan 21;19(3):339-46
pubmed: 23372355
Liver Transpl Surg. 1995 Jul;1(4):249-55
pubmed: 9346575
Cancer Biomark. 2007;3(2):79-87
pubmed: 17522429
Hepatol Int. 2010 Jul 13;4(3):569-76
pubmed: 21063479
Hepatol Res. 2014 Oct;44(10):E11-25
pubmed: 23834468
J Hepatol. 2015 Apr;62(4):848-54
pubmed: 25450201
Hepat Mon. 2015 Jul 22;15(7):e28806
pubmed: 26300931
J Gastroenterol Hepatol. 2008 Oct;23(10):1541-8
pubmed: 18422961
Am J Gastroenterol. 1999 Mar;94(3):650-4
pubmed: 10086646
N Engl J Med. 2011 Sep 22;365(12):1118-27
pubmed: 21992124
Tumour Biol. 1992;13(5-6):316-23
pubmed: 1283927
Scand J Gastroenterol. 2009;44(7):861-6
pubmed: 19391065
Infect Agent Cancer. 2020 Nov 23;15(1):70
pubmed: 33292429
Digestion. 2013;87(2):121-31
pubmed: 23406785
World J Gastroenterol. 2019 Sep 28;25(36):5515-5529
pubmed: 31576097
Eur J Gastroenterol Hepatol. 2021 Feb 1;32(2):294-299
pubmed: 32796360
Scand J Gastroenterol. 2018 Jun;53(6):734-740
pubmed: 29667463
Liver Int. 2020 Aug;40(8):1987-1996
pubmed: 32301212
Tumour Biol. 2016 Oct 13;:
pubmed: 27739028
Clin Chem Lab Med. 2011 Apr;49(4):711-8
pubmed: 21231906
J Egypt Natl Canc Inst. 2014 Jun;26(2):79-85
pubmed: 24841158
Lancet. 2003 Dec 6;362(9399):1907-17
pubmed: 14667750
In Vivo. 2017 Jul-Aug;31(4):695-700
pubmed: 28652441
Hepatobiliary Pancreat Dis Int. 2018 Dec;17(6):487-495
pubmed: 30257796
J Hepatol. 2001 Apr;34(4):570-5
pubmed: 11394657